Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Research into the management of MLL

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses current research and drug developments to treat mixed lineage leukemia (MLL) rearranged acute lymphoblastic leukemia (ALL). Prof. Pieters states that numerous epigenetic abnormalities were discovered in MLL rearranged ALL, hence the market for drugs to modify these abnormalities has expanded. He highlights a few drugs that are currently being studied including demethylating agents such as azacitidine as well as monoclonal antibodies blinatumomab and inotuzumab.